As the government shutdown dragged on, some corporate practices at law firms have been financially squeezed, unable to collect fees from stalled initial public offerings. Meanwhile, some capital markets practices at law firms took creative approaches to work around the Securities and Exchange Commission’s gutted operations.

In a rare event, a biotechnology firm Gossamer Bio on Wednesday disclosed pricing details for a $230 million initial public offering without explicit SEC approval. The company is represented by Latham & Watkins, led by partner Matthew Bush, while Cooley, led by Charles Kim, represents the underwriters.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]